These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 39252946)

  • 1. Targeted anti-angiogenesis therapy for advanced osteosarcoma.
    Zhang Q; Xia Y; Wang L; Wang Y; Bao Y; Zhao GS
    Front Oncol; 2024; 14():1413213. PubMed ID: 39252946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteosarcoma: review of the past, impact on the future. The American experience.
    Jaffe N
    Cancer Treat Res; 2009; 152():239-62. PubMed ID: 20213394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current research progress in targeted anti-angiogenesis therapy for osteosarcoma.
    Liu Y; Huang N; Liao S; Rothzerg E; Yao F; Li Y; Wood D; Xu J
    Cell Prolif; 2021 Sep; 54(9):e13102. PubMed ID: 34309110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NOTCH Signaling in Osteosarcoma.
    Zhang Z; Wu W; Shao Z
    Curr Issues Mol Biol; 2023 Mar; 45(3):2266-2283. PubMed ID: 36975516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment.
    Tian H; Cao J; Li B; Nice EC; Mao H; Zhang Y; Huang C
    Bone Res; 2023 Feb; 11(1):11. PubMed ID: 36849442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in targeted therapy for osteosarcoma.
    Zhou W; Hao M; Du X; Chen K; Wang G; Yang J
    Discov Med; 2014 Jun; 17(96):301-7. PubMed ID: 24979249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-angiogenesis target therapy for advanced osteosarcoma (Review).
    Xie L; Ji T; Guo W
    Oncol Rep; 2017 Aug; 38(2):625-636. PubMed ID: 28656259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism and Role of Endoplasmic Reticulum Stress in Osteosarcoma.
    Zhu P; Li T; Li Q; Gu Y; Shu Y; Hu K; Chen L; Peng X; Peng J; Hao L
    Biomolecules; 2022 Dec; 12(12):. PubMed ID: 36551309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolism and senescence in the immune microenvironment of osteosarcoma: focus on new therapeutic strategies.
    Ying H; Li ZQ; Li MP; Liu WC
    Front Endocrinol (Lausanne); 2023; 14():1217669. PubMed ID: 37497349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of endostar combined multidrug chemotherapy in osteosarcoma.
    Xu M; Xu CX; Bi WZ; Song ZG; Jia JP; Chai W; Zhang LH; Wang Y
    Bone; 2013 Nov; 57(1):111-5. PubMed ID: 23912049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteosarcoma: Current Concepts and Evolutions in Management Principles.
    Pilavaki P; Gahanbani Ardakani A; Gikas P; Constantinidou A
    J Clin Med; 2023 Apr; 12(8):. PubMed ID: 37109122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PTEN in osteosarcoma: Recent advances and the therapeutic potential.
    Zheng C; Tang F; Min L; Hornicek F; Duan Z; Tu C
    Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188405. PubMed ID: 32827577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the VEGF Pathway in Osteosarcoma.
    Assi T; Watson S; Samra B; Rassy E; Le Cesne A; Italiano A; Mir O
    Cells; 2021 May; 10(5):. PubMed ID: 34069999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in Osteosarcoma.
    Panez-Toro I; Muñoz-García J; Vargas-Franco JW; Renodon-Cornière A; Heymann MF; Lézot F; Heymann D
    Curr Osteoporos Rep; 2023 Aug; 21(4):330-343. PubMed ID: 37329384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of tumor-associated macrophages in osteosarcoma progression - therapeutic implications.
    Huang Q; Liang X; Ren T; Huang Y; Zhang H; Yu Y; Chen C; Wang W; Niu J; Lou J; Guo W
    Cell Oncol (Dordr); 2021 Jun; 44(3):525-539. PubMed ID: 33788151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs.
    Chen C; Xie L; Ren T; Huang Y; Xu J; Guo W
    Cancer Lett; 2021 Mar; 500():1-10. PubMed ID: 33359211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances of nanomaterial-based anti-angiogenic therapy in tumor vascular normalization and immunotherapy.
    Xiao M; Shi Y; Jiang S; Cao M; Chen W; Xu Y; Xu Z; Wang K
    Front Oncol; 2022; 12():1039378. PubMed ID: 36523993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vessel state and immune infiltration of the angiogenesis subgroup and construction of a prediction model in osteosarcoma.
    Wu J; Jin Z; Lin J; Fu Y; Wang J; Shen Y
    Front Immunol; 2022; 13():992266. PubMed ID: 36405691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apurinic/apyrimidinic endonuclease 1 regulates angiogenesis in a transforming growth factor β-dependent manner in human osteosarcoma.
    Jiang X; Shan J; Dai N; Zhong Z; Qing Y; Yang Y; Zhang S; Li C; Sui J; Ren T; Li M; Wang D
    Cancer Sci; 2015 Oct; 106(10):1394-401. PubMed ID: 26250694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.